CN103796676B - 包含灭活的基孔肯亚病毒株的疫苗组合物 - Google Patents

包含灭活的基孔肯亚病毒株的疫苗组合物 Download PDF

Info

Publication number
CN103796676B
CN103796676B CN201280029793.9A CN201280029793A CN103796676B CN 103796676 B CN103796676 B CN 103796676B CN 201280029793 A CN201280029793 A CN 201280029793A CN 103796676 B CN103796676 B CN 103796676B
Authority
CN
China
Prior art keywords
chikungunya virus
vaccine
virus
chikungunya
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280029793.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103796676A (zh
Inventor
K·M·埃拉
苏玛斯·坎达斯瓦弥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bharat Biotech International Ltd
Original Assignee
Bharat Biotech International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech International Ltd filed Critical Bharat Biotech International Ltd
Publication of CN103796676A publication Critical patent/CN103796676A/zh
Application granted granted Critical
Publication of CN103796676B publication Critical patent/CN103796676B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201280029793.9A 2011-06-17 2012-06-18 包含灭活的基孔肯亚病毒株的疫苗组合物 Active CN103796676B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2067CH2011 2011-06-17
IN2067/CHE/2011 2011-06-17
PCT/IN2012/000432 WO2012172574A1 (en) 2011-06-17 2012-06-18 Vaccine composition comprising an inactivated chikungunya virus strain

Publications (2)

Publication Number Publication Date
CN103796676A CN103796676A (zh) 2014-05-14
CN103796676B true CN103796676B (zh) 2017-09-12

Family

ID=46601866

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280029793.9A Active CN103796676B (zh) 2011-06-17 2012-06-18 包含灭活的基孔肯亚病毒株的疫苗组合物

Country Status (12)

Country Link
US (1) US9844588B2 (enExample)
EP (1) EP2720715B1 (enExample)
JP (1) JP6147734B2 (enExample)
KR (1) KR101792684B1 (enExample)
CN (1) CN103796676B (enExample)
AU (1) AU2012269907B2 (enExample)
BR (1) BR112013032251B1 (enExample)
MY (1) MY173117A (enExample)
PH (1) PH12013502621A1 (enExample)
SG (1) SG10201607787RA (enExample)
WO (1) WO2012172574A1 (enExample)
ZA (1) ZA201309386B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013221187B9 (en) 2012-02-16 2018-01-04 Vlp Therapeutics, Inc. Virus like particle composition
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
JP6824154B2 (ja) * 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
WO2016038895A1 (en) 2014-09-11 2016-03-17 Vlp Therapeutics, Llc Flavivirus virus like particle
MY187459A (en) * 2015-07-16 2021-09-23 Bharat Biotech Int Ltd Vaccine compositions
WO2017123932A1 (en) * 2016-01-13 2017-07-20 United States, As Represented By The Secretary Of The Army Inactived vaccine for chikungunya virus
CN105906694B (zh) * 2016-05-05 2019-05-14 中国人民解放军军事医学科学院微生物流行病研究所 基孔肯亚病毒特异性检测抗原及其应用
BR112018074277A2 (pt) * 2016-05-27 2019-10-01 Univ Griffith vacina de alfavírus artrogênica
KR101875055B1 (ko) * 2016-10-19 2018-07-06 연세대학교 원주산학협력단 융합 단백질 및 그의 용도
KR102007203B1 (ko) * 2016-10-20 2019-08-05 연세대학교 원주산학협력단 융합 단백질 및 그의 용도
WO2018074884A1 (ko) * 2016-10-20 2018-04-26 연세대학교 원주산학협력단 재조합 단백질 및 그의 용도
CR20200082A (es) * 2017-09-21 2020-05-17 Valneva Se Virus chikungunya inmunogénico
US11648304B2 (en) 2017-11-03 2023-05-16 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR20200090893A (ko) 2017-11-30 2020-07-29 다케다 백신즈 인코포레이티드 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들
EP3728611A4 (en) 2017-12-20 2021-09-08 VLP Therapeutics, Inc. ALPHAVIRUS REPLICON PARTICLE
WO2019148086A1 (en) * 2018-01-26 2019-08-01 The Wistar Institute Of Anatomy And Biology Vaccines against mosquito-borne viruses, and methods of using same
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
KR102016668B1 (ko) 2018-12-19 2019-08-30 주식회사 엠디헬스케어 치쿤군야 바이러스 e2에 특이적으로 결합하는 dna 압타머 및 이의 용도
US11562105B2 (en) * 2019-07-11 2023-01-24 Yokogawa Electric Corporation System and method for module engineering with sequence libraries
KR102202082B1 (ko) 2019-09-25 2021-01-11 충북대학교 산학협력단 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
JP7644993B2 (ja) 2020-04-17 2025-03-13 ブイエルピー・セラピューティクス・インコーポレイテッド コロナウイルスワクチン
IL297564A (en) 2020-04-30 2022-12-01 Vlp Therapeutics Inc Cytokine immunotherapy
US20230398200A1 (en) * 2020-07-31 2023-12-14 Replicate Bioscience, Inc. Modified chikungunya viruses and sindbis viruses and uses thereof
CN117771353B (zh) * 2024-02-27 2024-05-14 中国医学科学院医学生物学研究所 一种以包膜蛋白为靶标的基孔肯雅病毒的mRNA疫苗及其制备方法
CN118561969B (zh) * 2024-08-02 2024-11-19 中国医学科学院医学生物学研究所 一种通过优化全长结构蛋白序列设计的基孔肯雅病毒广谱性mRNA疫苗
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030220A2 (en) * 2005-08-11 2008-03-13 The Board Of Regents Of The University Of Texas System Chikungunya virus infectious clones and uses thereof
CN101516395A (zh) * 2006-09-01 2009-08-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
WO2010062396A2 (en) * 2008-11-26 2010-06-03 Government Of The United States Of America , As Represented By The Secretary, Department Of Health And Human Services Virus like particle compositions and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009149583A (ja) * 2007-12-21 2009-07-09 National Institute Of Biomedical Innovation フラビウイルス感染症ワクチンおよびフラビウイルス感染症ワクチン用アジュバント

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030220A2 (en) * 2005-08-11 2008-03-13 The Board Of Regents Of The University Of Texas System Chikungunya virus infectious clones and uses thereof
CN101516395A (zh) * 2006-09-01 2009-08-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
WO2010062396A2 (en) * 2008-11-26 2010-06-03 Government Of The United States Of America , As Represented By The Secretary, Department Of Health And Human Services Virus like particle compositions and methods of use

Also Published As

Publication number Publication date
US20140120125A1 (en) 2014-05-01
PH12013502621A1 (en) 2014-02-03
JP2014520117A (ja) 2014-08-21
ZA201309386B (en) 2014-08-27
EP2720715B1 (en) 2017-08-09
AU2012269907A1 (en) 2014-01-09
AU2012269907B2 (en) 2017-05-18
WO2012172574A1 (en) 2012-12-20
CN103796676A (zh) 2014-05-14
KR20140043784A (ko) 2014-04-10
US9844588B2 (en) 2017-12-19
BR112013032251A2 (pt) 2016-12-20
SG10201607787RA (en) 2016-11-29
EP2720715A1 (en) 2014-04-23
JP6147734B2 (ja) 2017-06-14
BR112013032251B1 (pt) 2021-12-07
KR101792684B1 (ko) 2017-11-02
MY173117A (en) 2019-12-27

Similar Documents

Publication Publication Date Title
CN103796676B (zh) 包含灭活的基孔肯亚病毒株的疫苗组合物
AU2022204267B2 (en) Vaccine compositions
Zhang et al. Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells
WO2017220748A1 (en) Vaccine compositions comprising an attenuated mutant zika virus
CN103228293A (zh) 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂
EP3481848B1 (en) Genomic sequences encoding for an attenuated mutant zika virus
AU2020328159A1 (en) Single shot Chikungunya virus vaccine
WO2016079560A1 (en) A live and attenuated japanese encephalitis virus comprising a mutated m protein
BR112018000862B1 (pt) Composição de vacina estável, método para produção de antígeno de vírus da zika recombinante e método para preparação de antígeno de virião (vírus) inteiro inativado da zika para formulação de vacina de vírus da zika

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant